Access cutting-edge metastatic cancer treatment through this clinical trial at a research site in Huntersville. Study-provided care at no cost to qualified participants.
Access metastatic cancer specialists in Huntersville at no cost
This study follows strict safety protocols and ethical guidelines
All study-related metastatic cancer treatment provided free
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-00
Sponsor: Aulos Bioscience, Inc.
Check if you qualify for this metastatic cancer clinical trial in Huntersville, NC
If you're searching for metastatic cancer treatment options in Huntersville, NC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Huntersville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.